189 related articles for article (PubMed ID: 15064541)
1. [Ibogaine--the substance for treatment of toxicomania. Neurochemical and pharmacological action].
Kazlauskas S; Kontrimaviciūte V; Sveikata A
Medicina (Kaunas); 2004; 40(3):216-9. PubMed ID: 15064541
[TBL] [Abstract][Full Text] [Related]
2. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug.
Popik P; Layer RT; Skolnick P
Pharmacol Rev; 1995 Jun; 47(2):235-53. PubMed ID: 7568327
[No Abstract] [Full Text] [Related]
3. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review.
Maciulaitis R; Kontrimaviciute V; Bressolle FM; Briedis V
Hum Exp Toxicol; 2008 Mar; 27(3):181-94. PubMed ID: 18650249
[TBL] [Abstract][Full Text] [Related]
4. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.
Mash DC; Kovera CA; Pablo J; Tyndale RF; Ervin FD; Williams IC; Singleton EG; Mayor M
Ann N Y Acad Sci; 2000 Sep; 914():394-401. PubMed ID: 11085338
[TBL] [Abstract][Full Text] [Related]
5. The anti-addiction drug ibogaine and the heart: a delicate relation.
Koenig X; Hilber K
Molecules; 2015 Jan; 20(2):2208-28. PubMed ID: 25642835
[TBL] [Abstract][Full Text] [Related]
6. Development of novel medications for drug addiction. The legacy of an African shrub.
Glick SD; Maisonneuve IM
Ann N Y Acad Sci; 2000; 909():88-103. PubMed ID: 10911925
[TBL] [Abstract][Full Text] [Related]
7. The ibogaine medical subculture.
Alper KR; Lotsof HS; Kaplan CD
J Ethnopharmacol; 2008 Jan; 115(1):9-24. PubMed ID: 18029124
[TBL] [Abstract][Full Text] [Related]
8. Data accrue on "visionary" agent to interrupt addiction.
Morris K
Lancet; 1999 Nov; 354(9193):1883. PubMed ID: 10584734
[No Abstract] [Full Text] [Related]
9. Treatment of acute opioid withdrawal with ibogaine.
Alper KR; Lotsof HS; Frenken GM; Luciano DJ; Bastiaans J
Am J Addict; 1999; 8(3):234-42. PubMed ID: 10506904
[TBL] [Abstract][Full Text] [Related]
10. Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration.
Hough LB; Pearl SM; Glick SD
Life Sci; 1996; 58(7):PL119-22. PubMed ID: 8632705
[TBL] [Abstract][Full Text] [Related]
11. Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.
Corkery JM
Prog Brain Res; 2018; 242():217-257. PubMed ID: 30471681
[TBL] [Abstract][Full Text] [Related]
12. Facilitation of memory retrieval by the "anti-addictive" alkaloid, ibogaine.
Popik P
Life Sci; 1996; 59(24):PL379-85. PubMed ID: 8950313
[TBL] [Abstract][Full Text] [Related]
13. [Ibogaine - structure, influence on human body, clinical relevance].
Zdrojewicz Z; Kuszczak B; Olszak N
Pol Merkur Lekarski; 2016 Jul; 41(241):50-55. PubMed ID: 27734823
[TBL] [Abstract][Full Text] [Related]
14. DARK Classics in Chemical Neuroscience: Ibogaine.
Wasko MJ; Witt-Enderby PA; Surratt CK
ACS Chem Neurosci; 2018 Oct; 9(10):2475-2483. PubMed ID: 30216039
[TBL] [Abstract][Full Text] [Related]
15. Metabolic plasticity and the energy economizing effect of ibogaine, the principal alkaloid of Tabernanthe iboga.
Paškulin R; Jamnik P; Danevčič T; Koželj G; Krašovec R; Krstić-Milošević D; Blagojević D; Strukelj B
J Ethnopharmacol; 2012 Aug; 143(1):319-24. PubMed ID: 22751004
[TBL] [Abstract][Full Text] [Related]
16. Ibogaine in the treatment of substance dependence.
Brown TK
Curr Drug Abuse Rev; 2013 Mar; 6(1):3-16. PubMed ID: 23627782
[TBL] [Abstract][Full Text] [Related]
17. What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders.
Straub CJ; Rusali LE; Kremiller KM; Riley AP
J Med Chem; 2023 Jan; 66(1):107-121. PubMed ID: 36440853
[TBL] [Abstract][Full Text] [Related]
18. Ibogaine for treating drug dependence. What is a safe dose?
Schep LJ; Slaughter RJ; Galea S; Newcombe D
Drug Alcohol Depend; 2016 Sep; 166():1-5. PubMed ID: 27426011
[TBL] [Abstract][Full Text] [Related]
19. A contemporary history of ibogaine in the United States and Europe.
Alper KR; Beal D; Kaplan CD
Alkaloids Chem Biol; 2001; 56():249-81. PubMed ID: 11705112
[No Abstract] [Full Text] [Related]
20. NMDA antagonist properties of the putative antiaddictive drug, ibogaine.
Popik P; Layer RT; Fossom LH; Benveniste M; Geter-Douglass B; Witkin JM; Skolnick P
J Pharmacol Exp Ther; 1995 Nov; 275(2):753-60. PubMed ID: 7473163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
